Recently, Ab&B Bio-Tech Co., Ltd. (Ab&B Bio) has achieved significant progress - its supplementary application for a new class of quadrivalent influenza virus subunit vaccine (Huierkangxin HRK-X®) has been approved by the National Medical Products Administration (NMPA) of China. The target population for vaccination has been expanded to include individuals aged 6-35 months, making it the first and only quadrivalent influenza virus subunit vaccine approved for the entire population and full dosage in China. This provides a safer and higher-quality new option for influenza prevention and control in our country, and will further assist Ab&B Bio in expanding its market space, as well as making greater contributions to strengthening the public health defense line and safeguarding public health.

Source: Government Service Portal of the National Medical Products Administration

Currently, influenza virus remains one of the significant respiratory pathogens threatening human public health. Seasonal influenza outbreaks, sporadic cross-species transmission of influenza virus, and pandemics have a profound impact on human health and socio-economic development. Especially for infants, the elderly, and patients with underlying cardiopulmonary diseases, infection with influenza virus may lead to severe complications such as pneumonia, resulting in severe illness or death. Currently, influenza vaccination is the most effective measure to prevent influenza disease and outbreaks.
The approval of the marketing application for the quadrivalent influenza virus subunit vaccine for children aged 6 to 35 months marks another significant advancement in the subunit influenza vaccine family of Zhonghui Biotech. This high-quality vaccine, characterized by high purity, low vaccination side effects, excellent safety, and comprehensive protection, aligns with international vaccine development trends. It achieves a unified dosage form for people aged 6 months and above, greatly enhancing the convenience of vaccination and management. It provides a broader, safer, and more efficient immune protection for influenza prevention and control in China.